Antimicrobial susceptibility of streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)

Helio S. Sader, Rodrigo E. Mendes, Jennifer Le, Gerald Denys, Robert K. Flamm, Ronald N. Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluated the antimicrobial susceptibility of Streptococcus pneumoniae isolates collected worldwide over 20 years (1997-2016). A total of 65 993 isolates were consecutively collected (1 per infection episode) from North America (NA; n = 34 626; 2 nations), Europe (EUR; n = 19 123; 23 nations), the Asia-Pacific region (APAC; n = 7111; 10 nations), and Latin America (LATAM; n = 5133; 7 nations) and tested for susceptibility using reference broth microdilution methods. Resistant subgroups included multidrug-resistant (MDR; nonsusceptible to ≥3 classes of agents) and extensively drug-resistant (XDR; nonsusceptible to ≥5 classes). The isolates were collected primarily from respiratory tract infections (77.3%), and 25.4% were from pediatric patients. Penicillin susceptibility (≤0.06 mg/L) rates varied from 70.7% in EUR to 52.4% in APAC for all years combined. In NA, there was a slight improvement in susceptibility for the first few years of the program, from 66.5% in 1997-1998 to 69.4% in 1999-2000, followed by a decline until 2011-2012 (57.0%). Similar declines in penicillin susceptibility rates were observed in all regions, with the lowest rates of 67.3% in EUR (2011-2012), 41.6% in the APAC region (2007-2008), and 48.2% in LATAM (2013-2014). These declines were followed by improved susceptibility rates in all regions in later program years, with susceptibility rates of 55.6% to 71.8% in 2015-2016 (65.8% overall). Susceptibility rates to ceftriaxone, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole followed a similar pattern, with a decrease in the first 12-14 years and a continued increase in the last 6-8 years of the program. MDR and XDR frequencies were highest in APAC (49.8% and 17.3% overall, respectively) and lowest in LATAM (10.8% and 1.9% overall, respectively). The most active agents for MDR/XDR isolates were ceftaroline (99.7%/99.1% susceptible), tigecycline (96.8%/95.9% susceptible), linezolid (100.0%/100.0% susceptible), and vancomycin (100.0%/100.0% susceptible). S. pneumoniae susceptibility to many antibiotics increased in all regions in the last few years, and these increases may be related to PCV13 immunization, which was introduced in 2010.

Original languageEnglish (US)
Pages (from-to)S14-S22
JournalOpen Forum Infectious Diseases
Volume6
DOIs
StatePublished - Mar 15 2019

Fingerprint

Linezolid
Latin America
North America
Streptococcus pneumoniae
Penicillins
Clindamycin
Ceftriaxone
Sulfamethoxazole Drug Combination Trimethoprim
Erythromycin
Vancomycin
Infection
Tetracycline
Respiratory Tract Infections
Immunization
Pediatrics
Anti-Bacterial Agents
Pharmaceutical Preparations
tigecycline
T 91825

Keywords

  • PCV13
  • pneumococcal conjugate vaccine
  • S. pneumoniae
  • surveillance

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Antimicrobial susceptibility of streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region : Results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). / Sader, Helio S.; Mendes, Rodrigo E.; Le, Jennifer; Denys, Gerald; Flamm, Robert K.; Jones, Ronald N.

In: Open Forum Infectious Diseases, Vol. 6, 15.03.2019, p. S14-S22.

Research output: Contribution to journalArticle

@article{a7d61bffad9244e5a6e9b2e8a2a74448,
title = "Antimicrobial susceptibility of streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)",
abstract = "The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluated the antimicrobial susceptibility of Streptococcus pneumoniae isolates collected worldwide over 20 years (1997-2016). A total of 65 993 isolates were consecutively collected (1 per infection episode) from North America (NA; n = 34 626; 2 nations), Europe (EUR; n = 19 123; 23 nations), the Asia-Pacific region (APAC; n = 7111; 10 nations), and Latin America (LATAM; n = 5133; 7 nations) and tested for susceptibility using reference broth microdilution methods. Resistant subgroups included multidrug-resistant (MDR; nonsusceptible to ≥3 classes of agents) and extensively drug-resistant (XDR; nonsusceptible to ≥5 classes). The isolates were collected primarily from respiratory tract infections (77.3{\%}), and 25.4{\%} were from pediatric patients. Penicillin susceptibility (≤0.06 mg/L) rates varied from 70.7{\%} in EUR to 52.4{\%} in APAC for all years combined. In NA, there was a slight improvement in susceptibility for the first few years of the program, from 66.5{\%} in 1997-1998 to 69.4{\%} in 1999-2000, followed by a decline until 2011-2012 (57.0{\%}). Similar declines in penicillin susceptibility rates were observed in all regions, with the lowest rates of 67.3{\%} in EUR (2011-2012), 41.6{\%} in the APAC region (2007-2008), and 48.2{\%} in LATAM (2013-2014). These declines were followed by improved susceptibility rates in all regions in later program years, with susceptibility rates of 55.6{\%} to 71.8{\%} in 2015-2016 (65.8{\%} overall). Susceptibility rates to ceftriaxone, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole followed a similar pattern, with a decrease in the first 12-14 years and a continued increase in the last 6-8 years of the program. MDR and XDR frequencies were highest in APAC (49.8{\%} and 17.3{\%} overall, respectively) and lowest in LATAM (10.8{\%} and 1.9{\%} overall, respectively). The most active agents for MDR/XDR isolates were ceftaroline (99.7{\%}/99.1{\%} susceptible), tigecycline (96.8{\%}/95.9{\%} susceptible), linezolid (100.0{\%}/100.0{\%} susceptible), and vancomycin (100.0{\%}/100.0{\%} susceptible). S. pneumoniae susceptibility to many antibiotics increased in all regions in the last few years, and these increases may be related to PCV13 immunization, which was introduced in 2010.",
keywords = "PCV13, pneumococcal conjugate vaccine, S. pneumoniae, surveillance",
author = "Sader, {Helio S.} and Mendes, {Rodrigo E.} and Jennifer Le and Gerald Denys and Flamm, {Robert K.} and Jones, {Ronald N.}",
year = "2019",
month = "3",
day = "15",
doi = "10.1093/ofid/ofy263",
language = "English (US)",
volume = "6",
pages = "S14--S22",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Antimicrobial susceptibility of streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region

T2 - Results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016)

AU - Sader, Helio S.

AU - Mendes, Rodrigo E.

AU - Le, Jennifer

AU - Denys, Gerald

AU - Flamm, Robert K.

AU - Jones, Ronald N.

PY - 2019/3/15

Y1 - 2019/3/15

N2 - The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluated the antimicrobial susceptibility of Streptococcus pneumoniae isolates collected worldwide over 20 years (1997-2016). A total of 65 993 isolates were consecutively collected (1 per infection episode) from North America (NA; n = 34 626; 2 nations), Europe (EUR; n = 19 123; 23 nations), the Asia-Pacific region (APAC; n = 7111; 10 nations), and Latin America (LATAM; n = 5133; 7 nations) and tested for susceptibility using reference broth microdilution methods. Resistant subgroups included multidrug-resistant (MDR; nonsusceptible to ≥3 classes of agents) and extensively drug-resistant (XDR; nonsusceptible to ≥5 classes). The isolates were collected primarily from respiratory tract infections (77.3%), and 25.4% were from pediatric patients. Penicillin susceptibility (≤0.06 mg/L) rates varied from 70.7% in EUR to 52.4% in APAC for all years combined. In NA, there was a slight improvement in susceptibility for the first few years of the program, from 66.5% in 1997-1998 to 69.4% in 1999-2000, followed by a decline until 2011-2012 (57.0%). Similar declines in penicillin susceptibility rates were observed in all regions, with the lowest rates of 67.3% in EUR (2011-2012), 41.6% in the APAC region (2007-2008), and 48.2% in LATAM (2013-2014). These declines were followed by improved susceptibility rates in all regions in later program years, with susceptibility rates of 55.6% to 71.8% in 2015-2016 (65.8% overall). Susceptibility rates to ceftriaxone, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole followed a similar pattern, with a decrease in the first 12-14 years and a continued increase in the last 6-8 years of the program. MDR and XDR frequencies were highest in APAC (49.8% and 17.3% overall, respectively) and lowest in LATAM (10.8% and 1.9% overall, respectively). The most active agents for MDR/XDR isolates were ceftaroline (99.7%/99.1% susceptible), tigecycline (96.8%/95.9% susceptible), linezolid (100.0%/100.0% susceptible), and vancomycin (100.0%/100.0% susceptible). S. pneumoniae susceptibility to many antibiotics increased in all regions in the last few years, and these increases may be related to PCV13 immunization, which was introduced in 2010.

AB - The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluated the antimicrobial susceptibility of Streptococcus pneumoniae isolates collected worldwide over 20 years (1997-2016). A total of 65 993 isolates were consecutively collected (1 per infection episode) from North America (NA; n = 34 626; 2 nations), Europe (EUR; n = 19 123; 23 nations), the Asia-Pacific region (APAC; n = 7111; 10 nations), and Latin America (LATAM; n = 5133; 7 nations) and tested for susceptibility using reference broth microdilution methods. Resistant subgroups included multidrug-resistant (MDR; nonsusceptible to ≥3 classes of agents) and extensively drug-resistant (XDR; nonsusceptible to ≥5 classes). The isolates were collected primarily from respiratory tract infections (77.3%), and 25.4% were from pediatric patients. Penicillin susceptibility (≤0.06 mg/L) rates varied from 70.7% in EUR to 52.4% in APAC for all years combined. In NA, there was a slight improvement in susceptibility for the first few years of the program, from 66.5% in 1997-1998 to 69.4% in 1999-2000, followed by a decline until 2011-2012 (57.0%). Similar declines in penicillin susceptibility rates were observed in all regions, with the lowest rates of 67.3% in EUR (2011-2012), 41.6% in the APAC region (2007-2008), and 48.2% in LATAM (2013-2014). These declines were followed by improved susceptibility rates in all regions in later program years, with susceptibility rates of 55.6% to 71.8% in 2015-2016 (65.8% overall). Susceptibility rates to ceftriaxone, erythromycin, clindamycin, tetracycline, and trimethoprim-sulfamethoxazole followed a similar pattern, with a decrease in the first 12-14 years and a continued increase in the last 6-8 years of the program. MDR and XDR frequencies were highest in APAC (49.8% and 17.3% overall, respectively) and lowest in LATAM (10.8% and 1.9% overall, respectively). The most active agents for MDR/XDR isolates were ceftaroline (99.7%/99.1% susceptible), tigecycline (96.8%/95.9% susceptible), linezolid (100.0%/100.0% susceptible), and vancomycin (100.0%/100.0% susceptible). S. pneumoniae susceptibility to many antibiotics increased in all regions in the last few years, and these increases may be related to PCV13 immunization, which was introduced in 2010.

KW - PCV13

KW - pneumococcal conjugate vaccine

KW - S. pneumoniae

KW - surveillance

UR - http://www.scopus.com/inward/record.url?scp=85063162258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063162258&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofy263

DO - 10.1093/ofid/ofy263

M3 - Article

AN - SCOPUS:85063162258

VL - 6

SP - S14-S22

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

ER -